SCHEMBL5235779

SCHEMBL5235779

CC(C)Oc1ccc(N2CCCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
ALDH1A1 P00352 2/20 0.56
LMNA P02545 2/20 0.56
KMT2A Q03164 4/20 0.52
USP2 O75604 1/20 0.52
ALOX15 P16050 1/20 0.52
HSD17B10 Q99714 1/20 0.52
SMN1; SMN2 Q16637 5/20 0.51
KDM4E B2RXH2 1/20 0.51
GPR119 Q8TDV5 6/20 0.50
MEN1 O00255 3/20 0.49
TSHR P16473 1/20 0.49
NAMPT P43490 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
CYP2C19 P33261 1/20 0.47
PDK2 Q15119 1/20 0.47
CKS1B P61024 1/20 0.47
SKP1 P63208 1/20 0.47
SKP2 Q13309 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15703241 0.95 MAPT (0.61) MAPTALDH1A1LMNAKMT2AUSP2
SCHEMBL5233751 0.86 L3MBTL1 (0.66) MAPTALDH1A1LMNAKMT2AALOX15
SCHEMBL7078017 0.84 MAPT (0.60) MAPTALDH1A1LMNAKMT2ASMN1; SMN2
SCHEMBL5231173 0.83 GPR119 (0.70) MAPTALDH1A1LMNAKMT2ASMN1; SMN2
SCHEMBL13281422 0.83 MAPT (0.62) MAPTALDH1A1LMNAKMT2ASMN1; SMN2
SCHEMBL5233389 0.83 MAPT (0.56) MAPTALDH1A1LMNAKMT2AALOX15
SCHEMBL5233944 0.83 MAPT (0.56) MAPTALDH1A1LMNAKMT2AALOX15
SCHEMBL5573222 0.83 MAPT (0.76) MAPTALDH1A1LMNAKMT2AUSP2
SCHEMBL3194630 0.82 MAPT (0.61) MAPTALDH1A1LMNAKMT2ASMN1; SMN2
SCHEMBL5236861 0.82 MAPT (0.61) MAPTALDH1A1LMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070219234-A1 Thienopyridine Derivatives SANKYO COMPANY, LIMITED (JP) 2007-09-20 US disclosed
EP-1764367-A1 THIENOPYRIDINE DERIVATIVES Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219234-A1 Thienopyridine Derivatives RASGRP1, NRAS, HRH3 MAPT 4452/4885ALDH1A1 1073/4885LMNA 4549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.